Literature DB >> 22798538

Clinical outcomes and predictors for ESRD and mortality in primary GN.

Yu-Hsiang Chou1, Yu-Chung Lien, Fu-Chang Hu, Wei-Chou Lin, Chih-Chin Kao, Chun-Fu Lai, Wen-Chih Chiang, Shuei-Liong Lin, Tun-Jun Tsai, Kwan-Dun Wu, Yung-Ming Chen.   

Abstract

BACKGROUND AND OBJECTIVES: Relatively little is known about the long-term outcomes of different histologic types of primary glomerulonephritis in Asian populations. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From 1993 to 2006, 987 patients undergoing renal biopsy were studied, and 580 patients (mean age=44.4 years, male=58.5%) with the four most common forms of glomerulonephritis (membranous nephropathy, focal and segmental glomerulosclerosis, IgA nephropathy, and minimal change disease) were selected for analysis. Median follow-up period was 5.9 (interquartile range=5.7) years.
RESULTS: The focal and segmental glomerulosclerosis group displayed the highest incidence of ESRD (25.8%) and the fastest decline of estimated GFR (4.6 ml/min per 1.73 m(2) per year). The IgA nephropathy group also had a higher rate of ESRD than the membranous nephropathy patients (19.2% versus 4.3%, P<0.001). In contrast, the membranous nephropathy group exhibited an overall death rate similar to the focal and segmental glomerulosclerosis group (17.2% versus 14.4%) but higher than the IgA nephropathy and minimal change disease patients (4.6% and 3.7%, respectively, P<0.001). The most powerful predictor for ESRD was focal and segmental glomerulosclerosis, whereas the strongest predictor for all-cause mortality was membranous nephropathy with higher proteinuria. Protectors against ESRD included male sex and higher hemoglobin.
CONCLUSIONS: Most predictors for ESRD and overall mortality found in this ethnic Chinese cohort were similar to other studies. However, some risk factors linked with distinct glomerular pathologies displayed differential clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798538      PMCID: PMC3430959          DOI: 10.2215/CJN.04500511

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  41 in total

Review 1.  Minimal change disease: a review.

Authors:  Tapasi C Saha; Harmeet Singh
Journal:  South Med J       Date:  2006-11       Impact factor: 0.954

2.  Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Research Group on Progressive Chronic Renal Disease.

Authors: 
Journal:  Nephron       Date:  1999       Impact factor: 2.847

3.  The epidemiology and prognosis of glomerulonephritis in Denmark 1985-1997.

Authors:  J Heaf; H Løkkegaard; S Larsen
Journal:  Nephrol Dial Transplant       Date:  1999-08       Impact factor: 5.992

Review 4.  Diagnosis and treatment of primary glomerular diseases. Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy.

Authors:  J K J Deegens; J F M Wetzels
Journal:  Minerva Urol Nefrol       Date:  2005-09       Impact factor: 3.720

5.  Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment.

Authors:  J J Rydel; S M Korbet; R Z Borok; M M Schwartz
Journal:  Am J Kidney Dis       Date:  1995-04       Impact factor: 8.860

6.  All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan.

Authors:  Chi Pang Wen; Ting Yuan David Cheng; Min Kuang Tsai; Yen Chen Chang; Hui Ting Chan; Shan Pou Tsai; Po Huang Chiang; Chih Cheng Hsu; Pei Kun Sung; Yi Hua Hsu; Sung Feng Wen
Journal:  Lancet       Date:  2008-06-28       Impact factor: 79.321

7.  Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants.

Authors:  D B Thomas; N Franceschini; S L Hogan; S Ten Holder; C E Jennette; R J Falk; J C Jennette
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

8.  Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population--epidemiology and outcome.

Authors:  Jeroen K J Deegens; Eric J Steenbergen; George F Borm; Jack F M Wetzels
Journal:  Nephrol Dial Transplant       Date:  2007-08-17       Impact factor: 5.992

9.  Adult minimal-change disease: clinical characteristics, treatment, and outcomes.

Authors:  Meryl Waldman; R John Crew; Anthony Valeri; Joshua Busch; Barry Stokes; Glen Markowitz; Vivette D'Agati; Gerald Appel
Journal:  Clin J Am Soc Nephrol       Date:  2007-04-11       Impact factor: 8.237

10.  Primary glomerulonephritis: an update on renal survival and determinants of progression.

Authors:  O Moranne; L Watier; J Rossert; B Stengel
Journal:  QJM       Date:  2008-02-02
View more
  23 in total

1.  Effects of 1,25(OH)2D3 on proliferation and apoptosis of human glomerular mesangial cells.

Authors:  Chun-Jiang Zhang; Dan Zhao; Xuan Yin; Hao Zhang; Li Ma; Jian-Ping Chen; Chun Liu; Xiao-Ping Yang
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2013-03-20       Impact factor: 2.801

Review 3.  The genetics and immunobiology of IgA nephropathy.

Authors:  Krzysztof Kiryluk; Jan Novak
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

4.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 5.  The next generation of therapeutics for chronic kidney disease.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Nat Rev Drug Discov       Date:  2016-05-27       Impact factor: 84.694

6.  Blood Pressure and Visit-to-Visit Blood Pressure Variability Among Individuals With Primary Proteinuric Glomerulopathies.

Authors:  Christine B Sethna; Kevin E C Meyers; Laura H Mariani; Kevin J Psoter; Crystal A Gadegbeku; Keisha L Gibson; Tarak Srivastava; Matthias Kretzler; Tammy M Brady
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

7.  Patient characteristics and outcomes by GN subtype in ESRD.

Authors:  Michelle M O'Shaughnessy; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

8.  Native kidney biopsies in older adults: disease spectrum, long-term kidney and patient survival and safety.

Authors:  Hui Zhuan Tan; Benson Siow; Jason Chon Jun Choo; Alwin Hwai Liang Loh; Fiona Hui Ing Yeo; Irene Mok; Puay Hoon Tan; Choong Meng Chan; Chieh Suai Tan; Keng Thye Woo; Cynthia Ciwei Lim
Journal:  Int Urol Nephrol       Date:  2022-02-12       Impact factor: 2.266

9.  Short term outcome of patients attending a renal-immunology clinic in central India.

Authors:  M Atlani; N K Kapoor; D Joshi; R Sutar; T Sharma; A Joshi
Journal:  J Postgrad Med       Date:  2022 Apr-Jun       Impact factor: 1.566

10.  Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study.

Authors:  Alan S Go; Thida C Tan; Glenn M Chertow; Juan D Ordonez; Dongjie Fan; David Law; Leonid Yankulin; Janet M Wojcicki; Sijie Zheng; Kenneth K Chen; Farzien Khoshniat-Rad; Jingrong Yang; Rishi V Parikh
Journal:  J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.